Listen to this story. Enjoy more audio and podcasts on iOS or Android.
Your browser does not support the element.
ON MARCH 6TH 1899 acetylsalicylic acid, better known as Aspirin, was registered at the imperial patent office in Berlin. The first-ever synthetic drug went on to become one of the world’s most successful medicines. On Aspirin’s 125th birthday its maker, Bayer, is in no mood for schnapps. In the run-up to the presentation of its new strategy and annual results on March 5th, analysts and investors speculated about the radical surgery that Bill Anderson, the newish chief executive, might announce in order to
→ Continue reading at The Economist
